Marker PH - Search Results

1

Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1).

Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, Michalek VN, Marker PH, Murar J, Buchwald H. Matthews AJ, et al. Among authors: marker ph. J Surg Res. 1997 Nov;73(1):35-40. doi: 10.1006/jsre.1997.5180. J Surg Res. 1997. PMID: 9441790

2

Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia.

Belcher JD, Marker PH, Geiger P, Girotti AW, Steinberg MH, Hebbel RP, Vercellotti GM. Belcher JD, et al. Among authors: marker ph. J Lab Clin Med. 1999 Jun;133(6):605-12. doi: 10.1016/s0022-2143(99)90191-9. J Lab Clin Med. 1999. PMID: 10360636

3

Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion.

Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Belcher JD, et al. Among authors: marker ph. Blood. 2000 Oct 1;96(7):2451-9. Blood. 2000. PMID: 11001897 Free article.

4

Cytomegalovirus inhibits p53 nuclear localization signal function.

Wang J, Belcher JD, Marker PH, Wilcken DE, Vercellotti GM, Wang XL. Wang J, et al. Among authors: marker ph. J Mol Med (Berl). 2001;78(11):642-7. doi: 10.1007/s001090000157. J Mol Med (Berl). 2001. PMID: 11269511

5

Human cytomegalovirus immediate early proteins upregulate endothelial p53 function.

Wang J, Marker PH, Belcher JD, Wilcken DE, Burns LJ, Vercellotti GM, Wang XL. Wang J, et al. Among authors: marker ph. FEBS Lett. 2000 Jun 2;474(2-3):213-6. doi: 10.1016/s0014-5793(00)01604-5. FEBS Lett. 2000. PMID: 10838087 Free article.

6

Time course of insulin resistance associated with feeding dogs a high-fat diet.

Rocchini AP, Marker P, Cervenka T. Rocchini AP, et al. Am J Physiol. 1997 Jan;272(1 Pt 1):E147-54. doi: 10.1152/ajpendo.1997.272.1.E147. Am J Physiol. 1997. PMID: 9038864

7

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens.

Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D. Kirstein MN, et al. Among authors: marker ph. Breast Cancer Res Treat. 2006 Apr;96(3):217-25. doi: 10.1007/s10549-005-9004-z. Breast Cancer Res Treat. 2006. PMID: 16502018

8

Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.

Williams BW, Chang JJ, Chi RM, Marker PH, Frethem CD, Le CT, Kratzke RA, Kirstein MN. Williams BW, et al. Among authors: marker ph. Cancer Lett. 2009 Oct 18;284(1):37-46. doi: 10.1016/j.canlet.2009.04.006. Epub 2009 May 12. Cancer Lett. 2009. PMID: 19442436

9

Metabolic and hemodynamic effects of a graded intracoronary insulin infusion in normal and fat anesthetized dogs: a preliminary study.

Rocchini AP, Wilson RF, Marker P, Cervenka T. Rocchini AP, et al. Hypertension. 1996 Mar;27(3 Pt 1):354-9. doi: 10.1161/01.hyp.27.3.354. Hypertension. 1996. PMID: 8698437

10

Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.

Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D, Kratzke RA. Kirstein MN, et al. Among authors: marker ph. Lung Cancer. 2007 Nov;58(2):196-204. doi: 10.1016/j.lungcan.2007.06.005. Epub 2007 Jul 25. Lung Cancer. 2007. PMID: 17651859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters